2024
Increases in functional connectivity between the default mode network and sensorimotor network correlate with symptomatic improvement after transcranial direct current stimulation for obsessive-compulsive disorder
Echevarria M, Batistuzzo M, Silva R, Brunoni A, Sato J, Miguel E, Hoexter M, Shavitt R. Increases in functional connectivity between the default mode network and sensorimotor network correlate with symptomatic improvement after transcranial direct current stimulation for obsessive-compulsive disorder. Journal Of Affective Disorders 2024, 355: 175-183. PMID: 38548207, DOI: 10.1016/j.jad.2024.03.141.Peer-Reviewed Original ResearchTranscranial direct current stimulationObsessive-compulsive disorderDirect current stimulationCurrent stimulationActive transcranial direct current stimulationSensorimotor networkOCD symptom dimensionsTreatment-resistant obsessive-compulsive disorderNeurobiological mechanisms of actionObsessive-compulsive disorder pathophysiologyWhole-brain connectivity analysisDaily tDCS sessionsSymptom improvementResting-state functional MRITDCS sessionsNon-invasive neuromodulation interventionsBrain stimulation interventionsFunctional connectivity changesAssociated with connectivityLeft deltoidSymptom dimensionsNeurobiological mechanismsLeft precuneusMode networkPre/postcentral gyri
2022
Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report
Kelmendi B, Kichuk S, DePalmer G, Maloney G, Ching T, Belser A, Pittenger C. Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon 2022, 8: e12135. PMID: 36536916, PMCID: PMC9758406, DOI: 10.1016/j.heliyon.2022.e12135.Peer-Reviewed Original ResearchObsessive-compulsive disorderTreatment of OCDPsychedelic treatmentTreatment-resistant obsessive-compulsive disorderRefractory obsessive-compulsive disorderOCD symptomsPsychological effectsSerotonin systemSingle experimental studyRecreational usersBrain serotonin systemTreatment of patientsClassic psychedelicsQuality of lifePsilocybinSymptomatic improvementCase reportClinical dataTherapeutic potentialEmotionsPatientsDisordersTreatmentNumber of conditionsCompulsionImagery Rescripting (ImRs) as an Adjunctive Treatment to Exposure and Response Prevention (ERP)-Resistant Obsessive-Compulsive Disorder: A Case Study
Maloney G, Kelmendi B, Pittenger C. Imagery Rescripting (ImRs) as an Adjunctive Treatment to Exposure and Response Prevention (ERP)-Resistant Obsessive-Compulsive Disorder: A Case Study. Clinical Case Studies 2022, 22: 174-191. DOI: 10.1177/15346501221123797.Peer-Reviewed Original ResearchObsessive-compulsive disorderTreatment-resistant obsessive-compulsive disorderResponse preventionOCD symptomsERP treatmentFirst-line psychological treatmentImagery rescriptingCompulsive checkingResistant obsessive-compulsive disorderPsychological treatmentSelective serotonin reuptake inhibitor (SSRI) pharmacotherapyBehavior therapyOCD sufferersLife satisfactionInterpersonal relationshipsERPTranscript excerptsTherapy adjunctInitial researchRescriptingCognitiveFurther researchIndividualsDisordersSpecific types
2021
Efficacy and safety of transcranial direct current stimulation as an add-on treatment for obsessive-compulsive disorder: a randomized, sham-controlled trial
Silva R, Brunoni A, Goerigk S, Batistuzzo M, Costa D, Diniz J, Padberg F, D’Urso G, Miguel E, Shavitt R. Efficacy and safety of transcranial direct current stimulation as an add-on treatment for obsessive-compulsive disorder: a randomized, sham-controlled trial. Neuropsychopharmacology 2021, 46: 1028-1034. PMID: 33452434, PMCID: PMC8115679, DOI: 10.1038/s41386-020-00928-w.Peer-Reviewed Original ResearchConceptsTreatment-resistant obsessive-compulsive disorderTranscranial direct current stimulationSupplementary motor areaBaseline Y-BOCS scoresActive transcranial direct current stimulationObsessive-compulsive disorderY-BOCS scoresDirect current stimulationAdverse eventsWeek 12Efficacy of tDCSCurrent stimulationCathodal transcranial direct current stimulationSham-controlled trialMild adverse eventsClinical Global ImpressionSham-controlled studyBetween-group differencesSymptoms of depressionSecondary outcomesPrimary outcomeImprovement subscaleGlobal ImpressionNeuromodulation therapiesTreatment resistance
2017
Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal Of Clinical Psychiatry 2017, 78: e766-e773. PMID: 28617566, DOI: 10.4088/jcp.16m11101.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAnxiety DisordersComorbidityDepressive DisorderDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSelective Serotonin Reuptake InhibitorsYoung AdultConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresN-acetylcysteineNAC groupYale-Brown Obsessive Compulsive Scale scoresTreatment-resistant OCD patientsBaseline Y-BOCS scoresTreatment-Resistant ObsessivePrimary outcome measureAnxiety symptomsDSM-IV criteriaSymptom dimensionsCompulsive Scale scoresSpecific OCD symptom dimensionsOCD symptom dimensionsAntioxidant medicationsAbdominal painPlacebo groupGlutamate modulatorsSecondary outcomesTertiary hospitalOutpatient clinicSeverity scoreWeek 16Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment
Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment. JAMA 2017, 317: 1358-1367. PMID: 28384832, DOI: 10.1001/jama.2017.2200.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsObsessive-compulsive disorderCognitive behavioral therapyTreatment of OCDReuptake inhibitorsBehavioral therapySystematic reviewFirst-line pharmacologic interventionPreferred initial treatment strategyTreatment-resistant obsessive-compulsive disorderInitial treatment strategyPrimary care settingTreatment-resistant casesDiagnosis of OCDFirst-line interventionEfficacy of neurolepticsDeep brain stimulationComputer-based cognitive behavioral therapyCase seriesPharmacologic interventionsAdjunctive useTreatment optionsTreatment advancesNeuromodulatory approaches
2016
Transcranial direct current stimulation for treatment-resistant obsessive-compulsive disorder: report on two cases and proposal for a randomized, sham-controlled trial
da Silva R, Brunoni A, Miguel E, Shavitt R. Transcranial direct current stimulation for treatment-resistant obsessive-compulsive disorder: report on two cases and proposal for a randomized, sham-controlled trial. Sao Paulo Medical Journal 2016, 134: 446-450. PMID: 27901245, PMCID: PMC10871858, DOI: 10.1590/1516-3180.2016.0155010716.Peer-Reviewed Original ResearchConceptsTreatment-resistant obsessive-compulsive disorderTranscranial direct current stimulationObsessive-compulsive disorderDirect current stimulationClinical trialsCurrent stimulationSham-controlled trialSerotonin reuptake inhibitorsSupplementary motor cortexPrimary obsessive-compulsive disorderCognitive behavioral therapySecondary outcomesPrimary outcomeReuptake inhibitorsSham interventionFirst patientCortical excitabilityMotor cortexUniversity HospitalWeek 4YBOCS scoresNeuromodulation techniquesNon-invasive techniqueBrain circuitsPatients
2006
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder
Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. Neurotherapeutics 2006, 3: 69-81. PMID: 16490414, PMCID: PMC3593363, DOI: 10.1016/j.nurx.2005.12.006.Peer-Reviewed Original ResearchConceptsGlutamate modulating agentsObsessive-compulsive disorderTreatment of OCDRecent magnetic resonance spectroscopy (MRS) studyTreatment-resistant obsessive-compulsive disorderModulating agentsGlutamate-modulating drugsThalamo-cortical circuitrySerotonin reuptake inhibitorsElevated glutamate levelsCurrent treatment strategiesMagnetic resonance spectroscopy studyCommon psychiatric disordersNovel pharmacotherapeutic agentsAmyotrophic lateral sclerosisNovel therapeutic interventionsFunctional neuroimaging studiesGlutamate hyperactivityComplete remissionReuptake inhibitorsGlutamatergic activityMetabolic hyperactivitySignificant morbidityCase reportCortico-striato
2005
Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial
Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH. Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial. Biological Psychiatry 2005, 58: 424-428. PMID: 15993857, DOI: 10.1016/j.biopsych.2005.04.043.Peer-Reviewed Original ResearchConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresYale-Brown Obsessive Compulsive ScaleTreatment-resistant OCD patientsAddition of riluzolePractical clinical benefitOpen-label trialGlutamate-modulating agentsSerious adverse effectsHamilton Depression InventoryAnxiety Inventory scoresObsessive Compulsive ScaleMost patientsStandard therapyGlutamatergic dysfunctionAugmentation therapyClinical benefitPrimary diagnosisStandard treatmentCorticostriatal pathwayTreatment respondersRiluzolePatientsDepression InventoryCitalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder
Fontenelle L, Mendlowicz M, Miguel E, Versiani M. Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder. The World Journal Of Biological Psychiatry 2005, 6: 57-59. PMID: 16097406, DOI: 10.1080/15622970510029740.Peer-Reviewed Original ResearchConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderSRI-resistant obsessive compulsive disorderResistant obsessive-compulsive disorderCombination of citalopramFirst-line treatmentAdequate trialReuptake inhibitorsCompulsive disorderPatientsCitalopramDisordersFuture studiesTrials
1997
Addition of desipramine to serotonin reuptake inhibitors in treatment- resistant obsessive-compulsive disorder
Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH. Addition of desipramine to serotonin reuptake inhibitors in treatment- resistant obsessive-compulsive disorder. American Journal Of Psychiatry 1997, 154: 1293-1295. PMID: 9286191, DOI: 10.1176/ajp.154.9.1293.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsReuptake inhibitorsObsessive-compulsive disorderObsessive-compulsive symptomsTreatment-resistant obsessive-compulsive disorderDouble-blind studyNorepinephrine reuptake inhibitorsReuptake of norepinephrineSerotonin reuptake inhibitorsAddition of desipraminePlacebo groupSuperior efficacyDepressive symptomsDesipramineSymptomsSignificant differencesPatientsTreatmentInhibitorsDisordersPlaceboNorepinephrineClomipramineReuptakeWeeks
1995
Lack of efficacy of clozapine monotherapy in refractory obsessive- compulsive disorder
McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, Price LH. Lack of efficacy of clozapine monotherapy in refractory obsessive- compulsive disorder. American Journal Of Psychiatry 1995, 152: 1812-1814. PMID: 8526253, DOI: 10.1176/ajp.152.12.1812.Peer-Reviewed Original ResearchConceptsTreatment-resistant obsessive-compulsive disorderRefractory obsessive-compulsive disorderGlobal improvement itemObsessive-compulsive disorderClozapine monotherapyClinical Global Impression ScaleHamilton Depression Rating ScaleMost adult patientsGlobal Impression ScaleDepression Rating ScaleLack of efficacyYale-Brown Obsessive Compulsive ScaleCGI global improvement itemObsessive Compulsive ScaleAdult patientsImpression ScaleDepressive symptomsImprovement itemsMonotherapyRating ScaleCompulsive ScaleDisordersPatientsTrialsEfficacy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply